Friday, 13 November 2026European Markets

EQVA Stock Impressive Jump On Tuesday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with EQVA (EQVA.OL) jumping 15.62% to kr5.18 on Tuesday while Oslo Børs Benchmark Index_GI jumped 0.57% to kr1,424.56.

EQVA's last close was kr4.48, 12% higher than its 52-week high of kr4.00.

About EQVA

Eqva ASA, provides technical solutions and services to maritime and land based industries in Norway and internationally. It operates in three segments: Products, Solutions & Renewables; Real Estate; and Other. The company provides technical installations to the land-based and maritime industry; and develops and operates small-scale hydropower plants. It also engages in real estate business. The company was formerly known as Havyard Group ASA and changed its name to Eqva ASA in November 2022. Eqva ASA was incorporated in 1999 and is headquartered in Kvinnherad, Norway.

Earnings Per Share

As for profitability, EQVA has a trailing twelve months EPS of kr-0.33.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.45%.

More news about EQVA (EQVA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com